Belei O, 2018 Romania
To evaluate small intestinal bacterial overgrowth (SIBO) in children with gastroesophageal reflux disease (GERD) after treatment with proton pump inhibitor (PPI), with or without the addition of L. reuteri DSM 17938. Glucose hydrogen breath test (GHBT) was used for assessment of SIBO. Healthy children, who did not receive any treatment, served as comparison group for the GHBT.
Open 12 weeks GHBT was performed before and after 12 weeks of treatment.
L. reuteri: + PPI: 64 (1×108 CFU) Placebo + PPI: 64 Healthy controls: 120
No GERD patient had SIBO before treatment. After 12 weeks of treatment, there was a significant difference in rate of SIBO:
• Placebo + PPI: 56% (36/64)
• L. reuteri + PPI: 6% (4/64)
• Healthy controls: 5% (6/120)
• The rate of GI symptoms related to SIBO was 64% in the pla cebo + PPI group vs. 0% in the L. reuteri + PPI, and the healthy control group, respectively.